Table 1—

Main clinical characteristics for the nonsmall cell lung cancer(NSCLC) and small cell lung cancer (SCLC) patient groups

CharacteristicsNSCLCSCLC
Patients n187161
Sex
 Male126 (67.4)117 (72.7)
 Female61 (32.6)44 (27.3)
Age yrs
 <60112 (59.9)70 (43.5)
 ≥6075 (40.1)91 (56.5)
Stage#
 IIB05 (3.8)
 IIIA16 (8.6)19 (14.6)
 IIIB57 (30.8)41 (31.5)
 IV112 (60.5)65 (50.0)
Response after second cycle
 CR+PR101 (54.0)128 (79.5)
 SD+PD86 (46.0)33 (20.5)
Patient treatment
 Etoposide2 (1.1)158 (98.1)
 Gemcitabine143 (76.5)0
 Platinum based drugs138 (73.8)117 (72.7)
 Other drugs60 (32.1)59 (36.6)
Treatment after second cycle
 Chemotherapy only135 (72.2)59 (36.6)
 Chemo- and radiotherapy43 (23.0)101 (62.7)
 Chemotherapy and surgery6 (3.2)0
 Chemotherapy, radiotherapy and surgery3 (1.6)1 (0.6)
Cycles administered n
 252 (27.8)17 (10.6)
 342 (22.5)15 (9.3)
 415 (8.0)52 (32.3)
 521 (11.2)20 (12.4)
 652 (27.8)49 (30.4)
 >65 (2.7)8 (5.0)
  • Data are presented as n (%), unless otherwise stated. One patient with mixed histology is not included in this table. CR: complete remission; PR: partial remission; SD: stable disease; PD: progressive disease. #: for two NSCLC patients (1.1%), stage was unknown. For 31 SCLC patients, the tumour stage was only classified as limited or extensive disease based on the Veterans Administration Lung Cancer Study Group criteria. Limited and extensive disease were regarded as stage II–III and IV, respectively. : patients with surgery or radiotherapy prior to the second cycle of chemotherapy were not included in the study.